Rev Esp Quimioter 2021;34(Suppl.1):35-37

Ceftolozane-tazobactam: When, how and why using it?

INMACULADA LÓPEZ MONTESINOS, MILAGRO MONTERO, LUISA SORLÍ, JUAN P. HORCAJADA

Published: 30 September 2021

http://www.doi.org/10.37201/req/s01.10.2021

Ceftolozane-tazobactam is currently the most active antipseudomonal agent, including multidrug-resistant extensively drug-resistant strains. Tazobactam provides additional activity against many extended-spectrum beta-lactamases Enterobacterales. Ceftolozane-tazobactam is formally approved for complicated urinary tract infection, complicated intra-abdominal infection, and hospital-acquired and ventilator-associated bacterial pneumonia. The clinical and microbiological success is over 70-80% in many series. However, resistant mutants to ceftolozane-tazobactam have been already described. Combination therapies with colistin or meropenem could be among the strategies to avoid the resistance emergence.

Rev Esp Quimioter 2021; 34(Suppl. 1):35-37 [Full-text PDF]